PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.52 - 1.58
1.19 - 3.37
354.5K / 984.1K (Avg.)
-1.64 | -0.94
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
30.49%
Revenue growth at 50-75% of CSIQ's 46.59%. Martin Whitman would worry about competitiveness or product relevance.
15.26%
Gross profit growth under 50% of CSIQ's 77.02%. Michael Burry would be concerned about a severe competitive disadvantage.
231.50%
EBIT growth above 1.5x CSIQ's 102.91%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
233.84%
Operating income growth above 1.5x CSIQ's 130.56%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
127.15%
Net income growth 1.25-1.5x CSIQ's 86.80%. Bruce Berkowitz would see if strategic cost cutting or product mix explains this difference.
118.18%
EPS growth 1.25-1.5x CSIQ's 85.29%. Bruce Berkowitz would check if strategic initiatives like cost cutting or better capital management explain the difference.
122.22%
Diluted EPS growth 1.25-1.5x CSIQ's 84.21%. Bruce Berkowitz would verify if strategic moves (e.g., targeted acquisitions, cost cuts) explain the edge.
1.12%
Share count expansion well above CSIQ's 0.32%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
6.90%
Diluted share count expanding well above CSIQ's 0.30%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
75.45%
OCF growth of 75.45% while CSIQ is zero. Bruce Berkowitz would see if small gains can expand into a larger competitive lead.
52.35%
FCF growth of 52.35% while CSIQ is zero. Bruce Berkowitz would see if modest improvements in free cash can accelerate further.
No Data
No Data available this quarter, please select a different quarter.
2.55%
5Y revenue/share CAGR under 50% of CSIQ's 179.05%. Michael Burry would suspect a significant competitive gap or product weakness.
-29.64%
Negative 3Y CAGR while CSIQ stands at 43.63%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
No Data
No Data available this quarter, please select a different quarter.
-129.65%
Negative 5Y OCF/share CAGR while CSIQ is at 0.00%. Joel Greenblatt would question the firm’s operational model or cost structure.
-212.65%
Negative 3Y OCF/share CAGR while CSIQ stands at 0.00%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
No Data
No Data available this quarter, please select a different quarter.
18.49%
Below 50% of CSIQ's 167.43%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
106.47%
Below 50% of CSIQ's 286.38%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
No Data
No Data available this quarter, please select a different quarter.
-26.07%
Negative 5Y equity/share growth while CSIQ is at 12.61%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-11.49%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
14.73%
AR growth well above CSIQ's 0.07%. Michael Burry fears inflated revenue or higher default risk in the near future.
-14.97%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
2.00%
Positive asset growth while CSIQ is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
2.08%
Under 50% of CSIQ's 15.87%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
0.25%
We have some new debt while CSIQ reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
4.28%
R&D dropping or stable vs. CSIQ's 9.23%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
-4.34%
We cut SG&A while CSIQ invests at 5.05%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.